Join to View Full Profile
7500 Fannin St Suite 100AHouston, TX 77054
Phone+1 713-795-0202
Dr. Darcourt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jorge Darcourt is an oncologist located in Houston and Sugar Land, TX, with subspecialties in breast cancer and genitourinary medical oncology. He completed his fellowship in hematology and medical oncology at Baylor College of Medicine and his residency in internal medicine at the University of Texas Health Science Center at Houston. Dr. Darcourt graduated from the University of Buenos Aires in 2000. He has experience in treating breast cancer, prostate cancer, urologic oncology, and bladder cancer. His published research has contributed to our understanding of cancer therapies, with multiple articles cited by other publications. He has been involved in clinical trials focusing on treatments for various types of breast cancer.
Education & Training
Harvard School of Public HealthMHCM, Master in Healthcare Management, 2016 - 2018
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2003 - 2006
University of Buenos AiresClass of 2000
Certifications & Licensure
TX State Medical License 2006 - 2025
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT) Start of enrollment: 2011 Sep 01
- PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
- NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer Start of enrollment: 2013 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsPrognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer.Kevin T Tran, Neil C Chevli, Jay A Messer, Waqar Haque, Andrew M Farach
Clinical and Translational Radiation Oncology. 2023-03-01 - 18 citationsA Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer.Kai Sun, Yitian Xu, Licheng Zhang, Polly Niravath, Jorge Darcourt
Clinical Cancer Research. 2022-10-14 - 69 citationsA phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer.Andrew W Chung, Kartik Anand, Ann C Anselme, Alfred A Chan, Nakul Gupta
Science Translational Medicine. 2021-12-15
Press Mentions
Report Shows Drop in Cancer Deaths, but Troubling Data for Women and Younger AdultsJanuary 16th, 2025- Managing Cancer Care During COVID-19: 4 Oncologists Weigh InJuly 22nd, 2020
New Technology Reduces Chemotherapy-Related Hair Loss for Patients at Houston Methodist SL HospitalJanuary 31st, 2019- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
